MS HB98

Extends from July 1, 2021 to July 1, 2024 the authorization for hospice medical directors to prescribe controlled substances for terminal disease pain without conducting an in-person face-to-face visit with the patient

Allows this exception to override any conflicting rules or regulations from licensing agencies

Maintains existing requirements that all other controlled substance prescriptions (Schedules II-V) generally require a valid prescription with at least one in-person medical evaluation

Preserves exceptions for covering practitioners, telemedicine authorized under state or federal law, and emergency situations as defined by the State Board of Pharmacy

Effective date of July 1, 2021